About us
Belgium-based biotech company
Founded in 2018, Dendrogenix develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology

Technology
The origin of the discovery of our Dendrogenins results from the study of tamoxifen's mode of action through functional genomics studies. Tamoxifen has been the first drug used to treat hormone-dependent breast cancer. During metabolic and functional genomics studies associated with the activity of this drug, an ancillary pathway for Tamoxifen which is involved in the control of cell differentiation has been identified by Dr. Marc Poirot and his scientific team at the INSERM Institute in Toulouse. This pathway is based on serial sterol metabolism that generates molecules with original structures called Dendrogenins. These molecules stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors.
Our Team
We stay on top of our industry by being experts.
Board of Directors

Jean-Michel FOIDART
MD, PhD
CHAIRMAN OF THE BOARD

Stéphane SILVENTE
MBA
CO-FOUNDER

Philippe LEFEBVRE
MD, PhD
CO-FOUNDER

Emile LORIA (MD)
MEMBER OF THE BOARD

Patrick STRAGIER
NOSHAQ SPIN-OFFS REPRESENTATIVE

Caroline THIELEN (PhD)
SRIW REPRESENTATIVE
Partners









